WO2000001373A1 - Matieres et procedes d'encapsulation - Google Patents
Matieres et procedes d'encapsulation Download PDFInfo
- Publication number
- WO2000001373A1 WO2000001373A1 PCT/GB1999/002159 GB9902159W WO0001373A1 WO 2000001373 A1 WO2000001373 A1 WO 2000001373A1 GB 9902159 W GB9902159 W GB 9902159W WO 0001373 A1 WO0001373 A1 WO 0001373A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- capsules
- chitosan
- membrane
- reaction
- molecular weight
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 80
- 238000005538 encapsulation Methods 0.000 title claims description 24
- 239000000463 material Substances 0.000 title description 21
- 239000002775 capsule Substances 0.000 claims abstract description 153
- 229920001661 Chitosan Polymers 0.000 claims abstract description 104
- 239000012528 membrane Substances 0.000 claims abstract description 89
- 229920000642 polymer Polymers 0.000 claims abstract description 81
- 238000006243 chemical reaction Methods 0.000 claims abstract description 38
- 238000005755 formation reaction Methods 0.000 claims abstract description 33
- 230000035699 permeability Effects 0.000 claims abstract description 21
- 239000011162 core material Substances 0.000 claims abstract description 20
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 16
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 16
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 14
- 239000005017 polysaccharide Substances 0.000 claims abstract description 14
- 230000009918 complex formation Effects 0.000 claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical group O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 37
- 229940072056 alginate Drugs 0.000 claims description 37
- 229920000615 alginic acid Polymers 0.000 claims description 37
- 235000010443 alginic acid Nutrition 0.000 claims description 36
- 229920001525 carrageenan Polymers 0.000 claims description 11
- 239000012620 biological material Substances 0.000 claims description 9
- 239000000679 carrageenan Substances 0.000 claims description 9
- 229940113118 carrageenan Drugs 0.000 claims description 9
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 8
- 235000010418 carrageenan Nutrition 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 7
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 7
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 7
- 238000006731 degradation reaction Methods 0.000 claims description 7
- 150000002500 ions Chemical class 0.000 claims description 7
- 230000000704 physical effect Effects 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 206010068516 Encapsulation reaction Diseases 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 150000002978 peroxides Chemical class 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 abstract description 11
- 239000000243 solution Substances 0.000 description 78
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 230000015572 biosynthetic process Effects 0.000 description 30
- 229920000867 polyelectrolyte Polymers 0.000 description 23
- 230000035484 reaction time Effects 0.000 description 19
- 239000003094 microcapsule Substances 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 238000001556 precipitation Methods 0.000 description 12
- 238000009792 diffusion process Methods 0.000 description 11
- 150000004804 polysaccharides Chemical class 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000005588 protonation Effects 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000004132 cross linking Methods 0.000 description 9
- 230000009172 bursting Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000010668 complexation reaction Methods 0.000 description 7
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 229920000447 polyanionic polymer Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- -1 Ca2+ ions Chemical class 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 229920006317 cationic polymer Polymers 0.000 description 4
- 230000006196 deacetylation Effects 0.000 description 4
- 238000003381 deacetylation reaction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229920006158 high molecular weight polymer Polymers 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 4
- 235000010413 sodium alginate Nutrition 0.000 description 4
- 239000000661 sodium alginate Substances 0.000 description 4
- 229940005550 sodium alginate Drugs 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229920006318 anionic polymer Polymers 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229910021653 sulphate ion Inorganic materials 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241001315286 Damon Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000003918 potentiometric titration Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 101000654674 Homo sapiens Semaphorin-6A Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 102100032795 Semaphorin-6A Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229920001448 anionic polyelectrolyte Polymers 0.000 description 1
- 229920001586 anionic polysaccharide Polymers 0.000 description 1
- 150000004836 anionic polysaccharides Chemical class 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- ATHGHQPFGPMSJY-UHFFFAOYSA-Q spermidine(3+) Chemical compound [NH3+]CCCC[NH2+]CCC[NH3+] ATHGHQPFGPMSJY-UHFFFAOYSA-Q 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
Definitions
- the present invention relates to materials and methods relating to encapsulation, and in particular to encapsulating biological materials in capsules by complex formation between oppositely charged polymers.
- Encapsulation is currently employed in the food, agriculture and biotechnology and biomedical industries. Examples of these and potential applications are the encapsulation of islets for the treatment of diabetes mellitus, the use of encapsulated bioartificial organs targeted at treating neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington' s chorea, and in the control of chronic pain and the administration of human growth factors .
- One approach for forming capsules is based on complex formation between oppositely charged, high molecular weight polymers.
- a solution of a first polymer including a material to be encapsulated is preformed in droplets between about 0.2 -5.0mm in diameter and contacted with the second oppositely charged polymer.
- droplets of the first polymer and the material to be encapsulated are generated using a capillary or spraying device and contacted with the second polymer, e.g. by falling into a precipitation bath.
- the reaction between the polymers at the surface of the droplet forms a membrane around a liquid core including the encapsulated material .
- PECs polyelectrolyte complexes
- GB 2 135 954 A (Dautzenberg et al) describes a method of forming capsules from a pair of oppositely charged polyelectrolytes or a single polyelectrolyte and low molecular weight organic counter ions.
- preformed particles of a polyelectrolyte are contacted with a second polyelectrolyte or organic counter ions so that a membrane forms around the droplet thereby producing a capsule.
- the examples in this reference employ high molecular weight polyelectrolytes such as cellulose sulphate, carboxymethylcellulose or alginate.
- the lowest molecular weight polyelectrolyte disclosed is polydiallylmethylammonium chloride (40kD) , from which capsules were formed with sodium cellulose sulphate at pH 7.0.
- the reaction described in this application requires high levels of the organic counter ionic material to provide the necessary the mass transfer driving force to form a dense membrane skin. Further, the use of the organic counter ions suffers from the disadvantage that these materials can be toxic, the method does not provide a satisfactory trade-off between the permeability and the mechanical strength of the capsules, and the reaction times are exceedingly long (tens of minutes) .
- EP 0 152 898 A describes the use of oppositely charged polymers solutions to encapsulate biological materials, exemplifying the use of chitosan and alginate. This method uses high molecular weight polymers and consequently is carried out below pH 6.6 to ensure that these materials are soluble. Further, it relies on polyvalent metal cations (e.g. Ca 2+ ions) present in the cationic polymer solution to gel or harden the anionic polymer during capsule formation.
- polyvalent metal cations e.g. Ca 2+ ions
- US Patent No:4,808,707 discloses a method of forming capsules using chitosan and alginate, employing a pH of 6.1 or less and esterifying a proportion of the alginate in an attempt control the permeability of the membrane around the capsules.
- the reaction was also carried out in the presence of polyvalent metal ions (Ca 2+ ) , as with EP 0 152 898 A to promote gelling of beads during capsule formation.
- US Patent No: 5, 462, 866 (Vanderbilt University) describes a method for producing uniform capsules by forming capsules by individually enveloping droplets of polyanion solution with a collapsing annular sheet of polycation solution while the sheet is travelling downward at the same velocity as the droplets.
- This approach was employed as high molecular weight polyelectrolytes form viscous solutions leading to polyanion droplets distorting on impact with the surface of the polycation solution, and form irregular and highly distorted capsules.
- the patent discloses that the problem arises as a 0.2% solution of high molecular weight chitosan (>100kD) is about 10 times as viscous as a calcium chloride solution.
- Example 4 in this patent mentions "a 0.2% citosan [sic] solution with an approximate molecular weight of 20,000 daltons" .
- the chitosan used in this example is a high molecular weight polymer, probably having a molecular weight of 200kD.
- GB 2 145 992 A discloses a method for encapsulating cells by cross-linking droplets of chitosan by exposing the droplets to anionic materials such as polyaspartic acid and polyglutamic acid.
- anionic materials such as polyaspartic acid and polyglutamic acid.
- the chitosan has a high molecular weight and requires acidic pH to form solutions in water.
- US Patent No: 5, 089,272 (Shioya et al) relates to a method of producing capsules using ionic strength to adjust the permeability of the capsule.
- capsules are formed from a polyanionic polysaccharide and chitosan obtained from natural source materials having a molecular weight of 2800kD and 1600kD.
- the present invention relates to methods of producing capsules from oppositely charged ionic polymer solutions, wherein one of the polymers is oligomeric.
- one of the polymers is oligomeric.
- the use of an oligomeric polymer provides microcapsules having good mechanical properties and allows capsules to be formed at neutral or alkaline pH.
- the use of oligomers in conjunction with higher molecular weight polyelectrolytes can help to ameliorate some of the problem associated with the prior art methods discussed above.
- the present invention provides a method for encapsulating a core material within a capsule having a permeable or semipermeable membrane using a complex formation reaction between oppositely charged polymers, the method comprising: forming a droplet from a solution of an inner polymer comprising at least one positively or negatively charged polymer and the core material; and, contacting the droplet with a solution of an outer polymer comprising at least one polymer having an opposite charge to the polymer or polymers forming the droplet so that the polymers react to form a membrane around the droplet, wherein one of the polymers is an oligosaccharide with a molecular weight (MW) of less than 10. OkD and the reaction is carried out at a pH between about 6.6 and 7.5.
- MW molecular weight
- the present inventors surprisingly found that there is a significant correlation between the solubility of polysaccharides such as chitosan and their molecular weight, and that the use of an oligomeric polymer can both improve the solubility of the polymer at physiologically relevant pH and provide capsules having good mechanical properties.
- the present invention provides capsules having useful strength and permeability at physiologically appropriate pH by employing chitosan having a molecular weight of less than 20. OkD and more preferably, less than 10. OkD.
- the oligosaccharide is produced from a commercially available natural source materials such as chitosan (modified chitin) . While these materials are readily available, in general they have relatively high molecular weights and may require pretreatment to reduce their molecular weight so that they can then be used in the above method. Conveniently, the pretreatment is carried out using radical degradation to break down the polysaccharide so that it has a molecular weight below 10. OkD and is soluble at the pH of the encapsulation reaction, e.g. using methods such as radical degradation with peroxide, hydrolytic-enzymatic degradation, ⁇ -ray irradiation or acidic hydrolysis.
- the oligosaccharide has the further advantage that it is degraded in a controlled way, providing a consistent material and a degree of quality control required in many biomedical applications.
- the oligosaccharide has a degree of deacetylation >90%, and more preferably >95% and/or a polydispersity in MM less than 2.0, more preferably less than 1.8, and still more preferably less than about 1.5.
- the method does not require the use of high temperatures or polyvalent metal ions to promote gelling of the polymer solution and/or the use of organic counter ions in a precipitation bath.
- multivalent ions such as calcium, barium or iron are used to gel the polyelectrolyte.
- These beads are then coated with a solution of an oppositely charged polyelectrolyte.
- the solid bead is then converted into a permeable capsule by liquefying the gel, generally via the addition of a chelating agent such as EDTA or sodium citrate.
- a chelating agent such as EDTA or sodium citrate.
- these materials can be toxic and have a detrimental effect when present in methods for encapsulating biological materials.
- the method is preferably a single step reaction, in contrast to many of the prior art multi-step processes.
- the polymers are naturally occurring polymers to promote biocompatibility with encapsulated biological materials.
- the use of oligosaccharides or polysaccharides is especially preferred.
- the polymers can be negatively charged polymers such as alginate, i - carrageenan or ⁇ -carrageenan or carboxymethylcellulose. Chitosan is a preferred positively charged polymer.
- the oligosaccharide has a molecular weight less than 20. OkD, more preferably less than 10. OkD, and more preferably between about 0.5 and about 9. OkD, more preferably between about 0.6 and about 6. OkD and most preferably between about 1.0 and about 3. OkD.
- the other polymer has a molecular weight in the range 100-lOOOkD, more preferably in the range 100-500kD.
- the oligomeric polymer is positively charged, e.g. using the combination of oligochitosan and alginate.
- the polymer solutions may include low molecular weight monovalent metal salts (e.g. Na + or K + ) , or agents to promote isotonicity (e.g. mannitol) or buffer solutions.
- low molecular weight monovalent metal salts e.g. Na + or K +
- agents to promote isotonicity e.g. mannitol
- buffer solutions e.g. mannitol
- these and other additives can be included to help to maintain the osmotic pressure between the cells and polymer solutions in equilibrium.
- suitable anionic polymers for capsule formation include alginate, carboxymethylcellulose, xanthan, hyaluronic acid, gellan gum, cellulose sulphate, carrageenans (kappa- or iota-) and polyacrylic acid.
- Preferred cationic polymers include chitosan, glycol chitosan, chitosan derivatives, polyallylamines, quaternised polyamines, polydiallyldimethyl ammonium chloride (polyDADMAC) , polyDADMAC-acrylamide, polytrimethylammoethylacrylate-co-acrylamide, polymethylene-co-guanidine, polyvinylamine .
- the capsules can be produced by dropping one of the polymer solutions into a bath of the other.
- the concentration of the polymers is in the range 0.1 to 5.0%, more preferably in the range 0.5 to 2.0%.
- the droplets can be formed using passing one of the polymers through a capillary, by extrusion with gas or a liquid, using a spinning disk or by electrostatic generation.
- the droplets are formed from the higher molecular weight polymer, with the oligomeric polymer being the outer polymer.
- the capsules produced using the method have a diameter between 50 ⁇ m and 5.0mm.
- the diameter of the capsules can be controlled by varying the flow rate of the inner polymer solution or by controlling physical parameters such as the applied voltage, if electrostatic droplet generation is used, or the fluid stripping velocity, if the capsules are made by air/fluid stripping.
- the membrane around the capsules is typically 5 to 400/xm thick, and more preferably 50 to 200 ⁇ m thick. Preferably, the membrane is permeable or semi-permeable .
- the encapsulation method can also allow the molecular weight cut off of the membrane to be controlled between about 1 to about 300kD by selecting the polyelectrolyte, oligomer or monovalent salt concentration, pH, temperature or reaction time.
- the core material can be encapsulated by mixing it with the polymer solution which is formed into droplets.
- the method is particularly useful for encapsulating biological or biologically active materials, including cells, bacteria, enzymes, antibodies, drugs, cytokines or hormones, as it can be carried out biologically compatible pH, preferably at a pH greater than about 6.5, more preferably at a pH between about 6.6 and 7.5, more preferably at a pH between about 6.8 and 7.4 and more preferably at a pH between about 7.0 and 7.4, and more preferably at a pH between about 7.2 and 7.4.
- the present invention provides a method which additionally comprises the steps of: selecting a physical property required of a capsule; selecting the molecular weight of an oligosaccharide between 0.5 and 20. OkD that will provide capsules having the physical property when reacted with a core material and an oppositely charged polymer; reacting the polymers and core material as described above to produce the capsules; wherein the physical property is deformability and/or mechanical strength.
- the capsules have one or more of : (a) a high deformability of >70%, more preferably
- the present invention provides a method which comprises following the encapsulation of a core material as described above, the further step of formulating the capsules in a composition or other product .
- the present invention provides a polymeric capsule comprising a semipermeable membrane encapsulating a core material produced by the above method. In a further aspect, the present invention provides a polymeric capsule comprising a semipermeable membrane encapsulating a core material produced by the above method for use in a method of medical treatment .
- Figure 1 Schematic representation of capsule formation via polyelectrolyte complexation.
- A droplet generation apparatus
- B contacting of oppositely charged polymers
- C capsule with membrane.
- Figure 2 Variation in the mechanical properties of the chitosan-alginate capsules with changes in the molecular weight of chitosan.
- Figure 4 Permeability of capsules synthesized in various solutions (for conditions see Table 1) . Solute diffusion of dextran of different molar masses.
- Figure 5 Relative cross linking density of capsule membranes in function of membrane/capsule volume ratio for conditions see Table 1.
- the arrows indicate the direction of the pH increase (from 6.0 to 7.0) .
- Capsules with a permeable, or semipermeable wall, and a liquid core can be formed by introducing the liquid droplets from aqueous solution of an anionic polyelectrolyte into an aqueous solution of a countercharged cationic polyelectrolyte (Figure 1A) .
- the capsule wall consists of polymer complex which is a product of the reaction of oppositely charged polyelectrolytes ( Figure IB) .
- the anionic polymer is generally interior to the cationic polymer, the reverse can also be applied.
- Figure 1C shows a schematic of a membrane generated by the interaction of the two polymers .
- Section A and examples 1 to 23 describe microcapsules production with different polymers and reaction conditions. Following on from this, a series of thermodynamic and kinetic experiments using the preferred chitosan/alginate system are described in section B. Finally, in vivo implantation experiments are described in section C.
- Keltone HV - Sodium Alginate (lot. 54650A) was obtained from Kelco/NutraSweet (San Diego, CA, USA) .
- An intrinsic viscosity [ ⁇ ] of 780mL/g was measured in 0. IM NaCl at 20°C in a capillary viscosimeter (Viscologic TI 1, SEMA Tech, France) . This reflects to MM of 390kD.
- Chitosan Samples with varying molar masses (l-10kD) were obtained in controlled radical degradation via continuous addition of hydrogen peroxide (0.8-6.4mMol/g of polysaccharide) to 2.5% chitosan solution of pH 3.5 to 4.0 at 80°C.
- Molar masses of chitosan samples were estimated by GPC at a flow-rate of 0.5 mL/min.
- a Shodex OHpak SB-803 HQ column (Showa-Denko Company, Tokyo, Japan) was employed as the stationary phase, using 0.5M acetic acid/0.5M sodium acetate as an eluent, as recommended.
- Polyethylene glycol standards (PSS, Mainz, Germany) were used for column calibration and as a relative reference for MM calculation. All other reagents were of analytical grade.
- the degree of chitosan amino group ionization ( ⁇ ) at different pHs were determined from potentiometric titration curves, where 20 ml of 0.1% polymer solutions (pH 2.5) were titrated with 0.02M NaOH.
- Capsules were produced from a pair of oppositely charged polysaccharides. A 0.5-2% aqueous sodium alginate was prepared in deionized water or 0.9% NaCl. Approximately 4mL of this solution was introduced into a 5mL disposable syringe with a 0.4mm flat-cut needle (Becton Dickinson AG, Basel, Switzerland) .
- the droplets were sheared off for 60 sec at a flow rate lmL/min (kdScientific syringe pump - Bioblock Scientific, Frenkendorf, Switzerland) into 20mL of solution of 1% chitosan (M n varied between 2-3kD) at pH 6, 6.5 and 7.0 previously adjusted with IM NaOH respectively.
- the resulting microcapsules (2.5-3mm in diameter) were allowed to harden for 20 minutes under gentle stirring (200rpm) with small magnetic bar, filtered and rinsed with the solvent used for preparation of the polysaccharide solutions. Collected microcapsules (approx. 2mL in volume) were stored at 4°C in 0.9%
- chitosan molar mass on the relative mechanical strength of the prepared chitosan/alginate capsules was determined as follows.
- the oligochitosan generally had a "lower critical oligomer chain length" (M n >l-2kD) for stable capsule formation, with a maximum in mechanical capsule strength observed at a MM of 2-3kD. All oligochitosan samples used in the mechanism and kinetics studies were prepared within this range (2.2-2.8kD) .
- Chitosan Conversion Determination Samples of 400mL of chitosan solutions were withdrawn from the reaction bath every 5 minutes during capsule formation and characterized by using the aforementioned chromatographic method. By assuming that the total concentration of the solute is proportional to the GPC elution curve area (Beers' Law) , the conversion and MM of chitosan were calculated from the respective chromatogram derivatives.
- the dextran concentrations were proportional to the maximum heights of the detected chromatographic peaks (Beers' Law) and calculated with respect to the initial polymer standard concentration, which is the concentration of the dextran standard with the defined MM at time 0 (immediately following the addition of 2ml of standard solution into 1ml of capsules) .
- the membrane permeability calculated from decrease in dextran concentration, was maximal at 33.3% of polymer diffusion.
- the cut-off of the microcapsules was defined as the lowest MM of dextran for which diffusion was smaller than 2% after 3 hours.
- capsules were produced according to the following protocol.
- Solvents used included water, as well as aqueous solution of low molecular weight monovalent metal salts, and isotonic or buffer solutions.
- reaction time varied between 1 minute and three hours.
- the capsules are stable after a few seconds, but 1 minute is a preferred minimum reaction time .
- Alginate can be replaced by either iota-or kappa-carrageenan or carboxymethylcellulose (CMC) (Table I) •
- Capsule size 50 ⁇ m to 5.0mm in diameter, exemplifying the ranges 3 -4mm, 0.4 -0.6mm and 0.8 -1.0mm.
- FIG. 2 shows a schematic graph correlating the mechanical strength of the capsules with the molecular weight (MW) of the outer polymer (chitosan) . This shows that below 600 daltons, no capsules were precipitated under the conditions used, while above 10. OkD, the membrane formed had low mechanical strength. Between these extremes, stable capsule were generated with a maximum at a molecular weight of 2,000 daltons.
- MW molecular weight
- Example 1 The following examples are provided by way of illustration to demonstrate how the capsules can be produced under a range of different conditions.
- Example 1
- the droplets Immediately after entry into the precipitation bath, the droplets become covered with a membrane of the alginate/chitosan complex. After 20 minutes, the capsules were separated by decanting and washed with water.
- the spherical transparent microcapsules with good mechanical properties have a diameter of 3 -4mm.
- Example 2 Following the procedure of Example 1, 0.75-1% w/v of sodium alginate solution in 0.9% NaCl was added dropwise to precipitation bath of 1-2% w/v oligochitosan solution also in 0.9% NaCl.
- the chitosan had molecular weight of 3-6 KD and a solution pH of 6.7.
- the droplets become covered with membrane of the alginate/chitosan complex.
- the capsules were separated by decanting and washed with 0.9% NaCl.
- the spherical semi-transparent microcapsules with good mechanical properties have a diameter of 3 -4mm.
- Example 2 Following the procedure of Example 1, 0.75-1% w/v iota- carrageenan solution in water was added dropwise to precipitation bath of 0.5-2 %w/v oligochitosan solution in water.
- the chitosan had molecular weight 1-4 KD and its solution pH 6.9.
- the droplets became covered with a membrane of the iota-carrageenan/chitosan complex.
- the capsules were separated by decanting and washed with 0.9% NaCl.
- the spherical semi-transparent microcapsules with good mechanical properties have a diameter of 3 -4mm.
- Example 2 This example was carried out under the conditions used in Example 1 with a pH of 6.6.
- Example 6 This example was carried out under the conditions used in Example 1 with a reaction time of 40 minutes.
- Example 2 This example was carried out under the conditions used in Example 1 with a diameter of 0.8 -lmm.
- Example 2 This example was carried out under the conditions used in Example 1 with a diameter of 0.4 -0.6mm.
- Example 2 This example was carried out under the conditions used in Example 2 with a pH of 7.2 and the chitosan with a molecular weight of l-3kD.
- Example 2 with a diameter of 0.4 -0.6mm.
- Example 14 This example was carried out under the conditions used in Example 3 with a reaction time of 30 minutes.
- Example 3 This example was carried out under the conditions used in Example 3 with a diameter of 0.8-lmm.
- Example 3 This example was carried out under the conditions used in Example 3 with a diameter of 0.4-0.6mm.
- Example 4 with a diameter of 0.8 -lmm.
- Example 4 This example was carried out under the conditions used in Example 4 with a diameter of 0.4 -0.6mm.
- Example 21 This example was carried out under conditions used in Examples 1,6,7 and 8 where alginate and chitosan solutions were prepared in MOPS or HEPES buffer solutions .
- Membrane Formation Capsule permeability is controlled by the crosslinking density of the polymer network. As the membrane formation is an electrostatic process, pH and ionic strength influence complexation, with the protonation degree of chitosan being the key variable. Effect of Chitosan Protonation:
- Chitosan is weak base and has therefore a limited solubility in the higher pH region, i.e. precipitation occurs when the pH exceeds 6.0-6.5.
- precipitation occurs when the pH exceeds 6.0-6.5.
- Figure 3 shows the ionization degrees of 50kD chitosan and of two oligochitsan samples as a function of pH. At a pH 4.0 all samples are in their fully protonated form. However, with increasing pH protonation becomes highly dependent on the MM.
- the structure of the chitosan/alginate microcapsule membrane may be represented as alternative sequences of ionic interchain bonds and loop-like regions incorporating the uncoupled units of both chains. More compact membranes, with smaller "loops" and lower cutoffs, are formed at lower pHs, though only in the simple aqueous system (capsule prepared in water) .
- the introduction of low MM ions changes the polyelectrolyte solution conformation.
- longer chains, as in alginate transform from elongated into more compact coil structures.
- the short oligochitosan chains can more easily penetrate the alginate chain network and form thicker and less dense membranes.
- Table 2 summarizes the chitosan MM bound within the capsule membrane after 5 and 20 min of reaction.
- a very selective binding with respect to the MM of chitosan was observed during capsule formation in solutions which differ in pH and ionic strength. This effect is most prominent between capsules prepared in solutions with varying ionic strengths, such as water and 0.9% NaCl.
- the lower MM portion of chitosan is involved in membrane formation in salt free system. This specific complexation is caused by the so called polyelectrolyte effect. It has been shown for a number of interpolymer reactions between mixtures of oligomers that preferential binding to the longest chains takes place. However, this conclusion was primarily based on hydrogen bond complexation systems.
- the properties of the capsules vary remarkably as a function of the reaction conditions with the reaction time having the most profound influence on the process of binary capsule formation.
- the mechanical strength of the capsules increases with reaction time due to the increase of the capsule wall thickness (Table 4) .
- no significant differences in capsule permeability and cut-off were measured. This indicates that the process of "skin" formation during the first minutes of reaction controls the cut-off of the membrane.
- the subsequent diffusion controlled building-up of the inner membrane is responsible for the capsule's mechanical resistance.
- Table 5 illustrates that lower MM chitosans (2.6kD) form slightly denser membrane skins which limit oligocation diffusion and membrane build-up and, as a consequence, lead to mechanically less resistant capsules.
- decreasing the oligochitosan concentration changes the kinetics of membrane formation, engendering a significant reduction in mechanical stability.
- no significant difference in membrane permeability was observed.
- the capsule membrane grows more slowly at higher alginate concentrations (Table 6) . Oligocation diffusion seems to be retarded by the higher concentration of the polyanion chain network, which leads to thinner but due to the higher charge density, denser membrane with lower cut-off and higher mechanical resistance.
- the ionic strength and the pH of the solution utilized during the capsule formation process influence the structure of the alginate/oligochitosan membrane.
- the presence of a low MM salt (0.9% NaCl) accelerates the diffusion of the oligocations and leads to thicker capsule walls, although with lower relative crosslinking density.
- sodium chloride diminishes the effect of chitosan charge density on the permeability and the mechanical properties of capsules and shifts the cut-off of prepared membranes towards higher MM values.
- the permeability of the new alginate-oligochitosan microcapsules therefore, depends mainly of two factors: (1) the density of the membrane which forms the outer shell influences the cut-off, which is particularly important for capsules prepared in water, and (2) the final membrane thickness controls the kinetics of solute diffusion and is more important for capsules synthesized in 0 . 9% NaCl .
- the mechanical properties of capsules prepared at physiological conditions are primarily influenced by membrane thickness and can be controlled by parameters such as reaction time, oligochitosan MM and concentration.
- the alginate concentration significantly effects both mechanical and porosity characteristic of the capsule membrane.
- Keltone HV Keltone Chemical Company, UK
- 500mL in 0.9% NaCl was filtered over 5mm and 0.22mm filters (high pressure sterile filtration; 200mL) .
- the polyanion was extruded at 5mL/h using air stripping apparatus (22 G needle-Becton Dickinson, Ireland) into the chitosan receiving bath (30mL of 1% oligochitosan solution) and allowed to react in the bath for 5 minutes. After a further 5 minutes, the reaction solution was discarded over sterile plastic tube with nylon net. The capsules were then washed several times with PBS solution in a plastic tube (transferred 2x into the fresh PBS solution) .
- the method described herein can be applied to the encapsulation of a wide variety of materials.
- the method is particularly relevant to the encapsulation of biological or biologically active materials.
- the encapsulation can be used to physically protect the encapsulated material, e.g. from mechanical or environmental, or where the capsules are for implantation into a human or animal, to help to prevent or reduce an immune rejection to the material.
- Particularly preferred applications include:
- Capsules (2.5 mm in diameter) were obtained through a reaction between a 1% alginate (Keltone HV) solution and a chitosan solutions (pH 7.0, 0.9% NaCl, 20 min. reaction time, ambient temperature) .
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99929581A EP1094792A1 (fr) | 1998-07-06 | 1999-07-06 | Matieres et procedes d'encapsulation |
AU46366/99A AU4636699A (en) | 1998-07-06 | 1999-07-06 | Materials and methods relating to encapsulation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9814619.4A GB9814619D0 (en) | 1998-07-06 | 1998-07-06 | Materials and methods relating to encapsulation |
GB9814619.4 | 1998-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000001373A1 true WO2000001373A1 (fr) | 2000-01-13 |
Family
ID=10835022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/002159 WO2000001373A1 (fr) | 1998-07-06 | 1999-07-06 | Matieres et procedes d'encapsulation |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1094792A1 (fr) |
AU (1) | AU4636699A (fr) |
GB (1) | GB9814619D0 (fr) |
WO (1) | WO2000001373A1 (fr) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1129771A1 (fr) * | 2000-03-04 | 2001-09-05 | Primacare S.A. | Microcapsules |
WO2001087475A1 (fr) * | 2000-05-19 | 2001-11-22 | Ecole Polytechnique Federale De Lausanne | Materiaux et procedes d'encapsulation |
EP1184027A1 (fr) * | 2000-09-01 | 2002-03-06 | Primacare S.A. | Composition pour baton applicateur cosmetique |
US6733790B1 (en) | 1999-07-02 | 2004-05-11 | Cognis Iberia S. L. | Microcapsules and processes for making the same using various polymers and chitosans |
EP1502646A1 (fr) | 2003-08-01 | 2005-02-02 | The Procter & Gamble Company | Microcapsules |
WO2006064331A1 (fr) * | 2004-12-17 | 2006-06-22 | Medipol Sa | Particules hydrophiles a base de derives de chitosanes cationiques |
EP1702674A1 (fr) * | 2005-03-16 | 2006-09-20 | Cognis IP Management GmbH | Perles visibles |
WO2007031812A1 (fr) * | 2005-09-16 | 2007-03-22 | Medipol Sa | Particules a base de chitosane |
CN1313157C (zh) * | 2005-04-18 | 2007-05-02 | 天津大学 | 促进药物透皮传递的壳低聚糖组合物及其使用方法 |
EP1727525A4 (fr) * | 2004-03-23 | 2009-12-09 | Lytone Enterprise Inc | Capsule contenant du chitosane noye ou encapsule |
US7641917B2 (en) | 2001-05-30 | 2010-01-05 | Csir | Method of encapsulating an active substance |
US7897555B2 (en) | 2003-08-01 | 2011-03-01 | The Procter & Gamble Company | Microcapsules |
WO2012099482A3 (fr) * | 2011-01-18 | 2012-11-01 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies (A4Tec) | Dispositif, procédé et système pour la préparation de microcapsules |
CN102824332A (zh) * | 2012-09-14 | 2012-12-19 | 东北农业大学 | 一种抗菌肽缓释微胶囊的制备方法 |
RU2536225C1 (ru) * | 2014-01-28 | 2014-12-20 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство, обладающее гастропротекторной активностью |
WO2017089974A1 (fr) | 2015-11-23 | 2017-06-01 | Association For The Advancement Of Tissue Engineering Cell Based Technologies & Therapies Associação | Composition comprenant des complexes de polyélectrolyte, procédés et utilisations de cette dernière |
CN109172535A (zh) * | 2018-09-26 | 2019-01-11 | 青岛大学 | 聚电解质氧化石墨烯中空胶囊的制备及得到的中空胶囊 |
CN109172536A (zh) * | 2018-09-28 | 2019-01-11 | 青岛大学 | 具有多层三明治结构的中空胶囊的制备及得到的中空胶囊 |
CN109223726A (zh) * | 2018-09-28 | 2019-01-18 | 青岛大学 | 一种新型中空胶囊的制备方法及得到的新型中空胶囊 |
CN109316460A (zh) * | 2018-09-26 | 2019-02-12 | 青岛大学 | 一种多糖类聚电解质中空胶囊的制备方法及得到的中空胶囊 |
CN109338490A (zh) * | 2018-09-30 | 2019-02-15 | 青岛大学 | 一种中空多层结构纤维的制备方法及得到的纤维与其应用 |
CN109350606A (zh) * | 2018-09-26 | 2019-02-19 | 青岛大学 | 一种聚电解质中空胶囊的制备方法及得到的中空胶囊 |
CN109433122A (zh) * | 2018-09-28 | 2019-03-08 | 青岛大学 | 一种无机/有机核壳结构胶囊的制备方法及得到的胶囊 |
WO2020221361A1 (fr) * | 2019-04-30 | 2020-11-05 | 青岛大学 | Procédé de préparation de fibre à l'oxyde de graphène, et fibre ainsi obtenue |
US12312707B2 (en) | 2019-04-30 | 2025-05-27 | Qingdao University | Preparation method for graphene oxide fiber, and fiber obtained thereby |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0152898A2 (fr) * | 1984-02-15 | 1985-08-28 | Massachusetts Institute Of Technology | Procédé d'encapsulation et systèmes à base de matières actives encapsulées |
US5462866A (en) * | 1991-12-23 | 1995-10-31 | Vanderbilt University | Semipermeable microspheres encapsulating biological material |
WO1997026903A1 (fr) * | 1996-01-23 | 1997-07-31 | Mcgill University | Micro-organismes microencapsules issus du genie genetique pour applications cliniques |
-
1998
- 1998-07-06 GB GBGB9814619.4A patent/GB9814619D0/en not_active Ceased
-
1999
- 1999-07-06 EP EP99929581A patent/EP1094792A1/fr not_active Withdrawn
- 1999-07-06 WO PCT/GB1999/002159 patent/WO2000001373A1/fr not_active Application Discontinuation
- 1999-07-06 AU AU46366/99A patent/AU4636699A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0152898A2 (fr) * | 1984-02-15 | 1985-08-28 | Massachusetts Institute Of Technology | Procédé d'encapsulation et systèmes à base de matières actives encapsulées |
US5462866A (en) * | 1991-12-23 | 1995-10-31 | Vanderbilt University | Semipermeable microspheres encapsulating biological material |
WO1997026903A1 (fr) * | 1996-01-23 | 1997-07-31 | Mcgill University | Micro-organismes microencapsules issus du genie genetique pour applications cliniques |
Non-Patent Citations (1)
Title |
---|
NUSSINOVITCH A ET AL: "Liquid-core hydrocolloid capsules", FOOD HYDROCOLLOIDS, vol. 10, no. 1, 1996, pages 21 - 26, XP002121884 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733790B1 (en) | 1999-07-02 | 2004-05-11 | Cognis Iberia S. L. | Microcapsules and processes for making the same using various polymers and chitosans |
WO2001066241A1 (fr) * | 2000-03-04 | 2001-09-13 | Cognis Iberia, S.L. | Microcapsules - vi |
WO2001066240A1 (fr) * | 2000-03-04 | 2001-09-13 | Cognis Iberia, S.L. | Produits de soin pour la peau |
EP1129771A1 (fr) * | 2000-03-04 | 2001-09-05 | Primacare S.A. | Microcapsules |
WO2001087475A1 (fr) * | 2000-05-19 | 2001-11-22 | Ecole Polytechnique Federale De Lausanne | Materiaux et procedes d'encapsulation |
EP1184027A1 (fr) * | 2000-09-01 | 2002-03-06 | Primacare S.A. | Composition pour baton applicateur cosmetique |
WO2002017859A1 (fr) * | 2000-09-01 | 2002-03-07 | Cognis Iberia, S.L. | Preparations cosmetiques |
US7641917B2 (en) | 2001-05-30 | 2010-01-05 | Csir | Method of encapsulating an active substance |
US7897555B2 (en) | 2003-08-01 | 2011-03-01 | The Procter & Gamble Company | Microcapsules |
WO2005011855A1 (fr) * | 2003-08-01 | 2005-02-10 | The Procter & Gamble Company | Microcapsules |
EP1502646A1 (fr) | 2003-08-01 | 2005-02-02 | The Procter & Gamble Company | Microcapsules |
US7435715B2 (en) | 2003-08-01 | 2008-10-14 | The Procter & Gamble Company | Microcapsules |
EP1727525A4 (fr) * | 2004-03-23 | 2009-12-09 | Lytone Enterprise Inc | Capsule contenant du chitosane noye ou encapsule |
WO2006064331A1 (fr) * | 2004-12-17 | 2006-06-22 | Medipol Sa | Particules hydrophiles a base de derives de chitosanes cationiques |
EP1702674A1 (fr) * | 2005-03-16 | 2006-09-20 | Cognis IP Management GmbH | Perles visibles |
CN1313157C (zh) * | 2005-04-18 | 2007-05-02 | 天津大学 | 促进药物透皮传递的壳低聚糖组合物及其使用方法 |
WO2007031812A1 (fr) * | 2005-09-16 | 2007-03-22 | Medipol Sa | Particules a base de chitosane |
WO2012099482A3 (fr) * | 2011-01-18 | 2012-11-01 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies (A4Tec) | Dispositif, procédé et système pour la préparation de microcapsules |
CN102824332A (zh) * | 2012-09-14 | 2012-12-19 | 东北农业大学 | 一种抗菌肽缓释微胶囊的制备方法 |
RU2536225C1 (ru) * | 2014-01-28 | 2014-12-20 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство, обладающее гастропротекторной активностью |
US10576042B2 (en) | 2015-11-23 | 2020-03-03 | Association For The Advancement Of Tissue Engineering Cell Based Technologies & Therapies Associaçao | Composition comprising polyelectrolyte complexes, methods and uses thereof |
WO2017089974A1 (fr) | 2015-11-23 | 2017-06-01 | Association For The Advancement Of Tissue Engineering Cell Based Technologies & Therapies Associação | Composition comprenant des complexes de polyélectrolyte, procédés et utilisations de cette dernière |
CN109172535A (zh) * | 2018-09-26 | 2019-01-11 | 青岛大学 | 聚电解质氧化石墨烯中空胶囊的制备及得到的中空胶囊 |
CN109316460A (zh) * | 2018-09-26 | 2019-02-12 | 青岛大学 | 一种多糖类聚电解质中空胶囊的制备方法及得到的中空胶囊 |
CN109350606A (zh) * | 2018-09-26 | 2019-02-19 | 青岛大学 | 一种聚电解质中空胶囊的制备方法及得到的中空胶囊 |
CN109350606B (zh) * | 2018-09-26 | 2021-08-13 | 青岛大学 | 一种聚电解质中空胶囊的制备方法及得到的中空胶囊 |
CN109316460B (zh) * | 2018-09-26 | 2021-11-26 | 青岛大学 | 一种多糖类聚电解质中空胶囊的制备方法及得到的中空胶囊 |
CN109223726A (zh) * | 2018-09-28 | 2019-01-18 | 青岛大学 | 一种新型中空胶囊的制备方法及得到的新型中空胶囊 |
CN109433122A (zh) * | 2018-09-28 | 2019-03-08 | 青岛大学 | 一种无机/有机核壳结构胶囊的制备方法及得到的胶囊 |
CN109172536A (zh) * | 2018-09-28 | 2019-01-11 | 青岛大学 | 具有多层三明治结构的中空胶囊的制备及得到的中空胶囊 |
CN109223726B (zh) * | 2018-09-28 | 2021-08-13 | 青岛大学 | 一种新型中空胶囊的制备方法及得到的新型中空胶囊 |
CN109433122B (zh) * | 2018-09-28 | 2021-11-26 | 青岛大学 | 一种无机/有机核壳结构胶囊的制备方法及得到的胶囊 |
CN109338490A (zh) * | 2018-09-30 | 2019-02-15 | 青岛大学 | 一种中空多层结构纤维的制备方法及得到的纤维与其应用 |
WO2020221361A1 (fr) * | 2019-04-30 | 2020-11-05 | 青岛大学 | Procédé de préparation de fibre à l'oxyde de graphène, et fibre ainsi obtenue |
US12312707B2 (en) | 2019-04-30 | 2025-05-27 | Qingdao University | Preparation method for graphene oxide fiber, and fiber obtained thereby |
Also Published As
Publication number | Publication date |
---|---|
GB9814619D0 (en) | 1998-09-02 |
EP1094792A1 (fr) | 2001-05-02 |
AU4636699A (en) | 2000-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000001373A1 (fr) | Matieres et procedes d'encapsulation | |
Thu et al. | Alginate polycation microcapsules: I. Interaction between alginate and polycation | |
Pal et al. | Interpenetrating polymer network hydrogels of chitosan: applications in controlling drug release | |
Lee et al. | Advances in chitosan material and its hybrid derivatives: a review | |
Chaturvedi et al. | Sodium alginate in drug delivery and biomedical areas | |
Fundueanu et al. | Preparation and characterization of Ca-alginate microspheres by a new emulsification method | |
Gao et al. | Methods to prepare dopamine/polydopamine modified alginate hydrogels and their special improved properties for drug delivery | |
US5846530A (en) | Macrocapsules prepared from crosslinkable polysaccharides, polycations and/or lipids and uses therefor | |
Ko et al. | Preparation and characterization of chitosan microparticles intended for controlled drug delivery | |
Mohamadnia et al. | pH-sensitive IPN hydrogel beads of carrageenan-alginate for controlled drug delivery | |
Pal et al. | Alginates, blends and microspheres: controlled drug delivery | |
Wang et al. | Preparation, characterization and applications of low-molecular-weight alginate–oligochitosan nanocapsules | |
US20110111033A1 (en) | Hydrogel with covalently crosslinked core | |
Sobol et al. | Cytotoxicity study of novel water‐soluble chitosan derivatives applied as membrane material of alginate microcapsules | |
WO2000015272A1 (fr) | Cellules vivantes immobilisees dans un polymere, et applications correspondantes | |
Ahn et al. | Single-step synthesis of alginate microgels enveloped with a covalent polymeric shell: A simple way to protect encapsulated cells | |
Rakshit et al. | Research progresses on carboxymethyl xanthan gum: Review of synthesis, physicochemical properties, rheological characterization and applications in drug delivery | |
Gin et al. | Agarose encapsulation of islets of Langerhans: reduced toxicity in vitro | |
Marković et al. | Alginates and similar exopolysaccharides in biomedical application and pharmacy: Controled delivery of drugs | |
Singha et al. | Applications of alginate-based bionanocomposites in drug delivery | |
Akshaya et al. | A review on hydrophobically associated alginates: approaches and applications | |
Xia et al. | Fabrication of Ca-alginate microspheres by diffusion-induced gelation in double emulsion droplets for oral insulin | |
Rana et al. | Modification of gums: synthesis techniques and pharmaceutical benefits | |
Sarkar et al. | Modified alginates in drug delivery | |
Leirvåg | Strategies for stabilising calcium alginate gel beads: Studies of chitosan oligomers, alginate molecular weight and concentration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999929581 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999929581 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09743172 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999929581 Country of ref document: EP |